BR0211358A - Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis - Google Patents
Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveisInfo
- Publication number
- BR0211358A BR0211358A BR0211358-9A BR0211358A BR0211358A BR 0211358 A BR0211358 A BR 0211358A BR 0211358 A BR0211358 A BR 0211358A BR 0211358 A BR0211358 A BR 0211358A
- Authority
- BR
- Brazil
- Prior art keywords
- fluorophenyl
- physiologically acceptable
- pyridylmethylaminomethyl
- acceptable salts
- compound
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 4
- -1 2- [5- (4-fluorophenyl) -3-pyridylmethylaminomethyl] -chroman compound Chemical class 0.000 title abstract 2
- 208000016285 Movement disease Diseases 0.000 abstract 2
- HKFMQJUJWSFOLY-NRFANRHFSA-N 1-[(2s)-3,4-dihydro-2h-chromen-2-yl]-n-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]methanamine Chemical compound C1=CC(F)=CC=C1C1=CN=CC(CNC[C@H]2OC3=CC=CC=C3CC2)=C1 HKFMQJUJWSFOLY-NRFANRHFSA-N 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"USO DO COMPOSTO DE 2-[5-(4-FLUOROFENIL)-3PIRIDILMETILAMINOMETIL]-CROMANO E SEUS SAIS FISIOLOGICAMENTE ACEITáVEIS". A presente invenção refere-se ao uso do composto de (R/S)-(/+)-2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano ou de um sal fisiologicamente aceitável do mesmo e do composto de (S)-(+)-2-[5-(4-fluorofenil)3-piridilmetilaminometil]-cromano ou um sal fisiologicamente aceitável do mesmo para a fabricação de um medicamento destinado ao tratamento de distúrbios do movimento extrapiramidal e/ou tratamento dos efeitos adversos nos distúrbios do movimento extrapiramidal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01118097 | 2001-07-26 | ||
| PCT/EP2002/007660 WO2003009835A2 (en) | 2001-07-26 | 2002-07-10 | Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0211358A true BR0211358A (pt) | 2004-09-21 |
Family
ID=8178137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0211358-9A BR0211358A (pt) | 2001-07-26 | 2002-07-10 | Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7872030B2 (pt) |
| EP (1) | EP1408964B1 (pt) |
| JP (1) | JP2004538289A (pt) |
| KR (1) | KR20040029325A (pt) |
| CN (1) | CN1292749C (pt) |
| AR (1) | AR037496A1 (pt) |
| AT (1) | ATE352302T1 (pt) |
| AU (1) | AU2002355170B2 (pt) |
| BR (1) | BR0211358A (pt) |
| CA (1) | CA2455621C (pt) |
| CY (1) | CY1107616T1 (pt) |
| DE (1) | DE60217870T2 (pt) |
| DK (1) | DK1408964T3 (pt) |
| ES (1) | ES2280602T3 (pt) |
| HU (1) | HUP0402092A3 (pt) |
| MX (1) | MXPA04000775A (pt) |
| MY (1) | MY134059A (pt) |
| PE (1) | PE20030277A1 (pt) |
| PL (1) | PL208258B1 (pt) |
| PT (1) | PT1408964E (pt) |
| RU (1) | RU2297833C2 (pt) |
| SI (1) | SI1408964T1 (pt) |
| WO (1) | WO2003009835A2 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007013830A1 (en) | 2005-07-26 | 2007-02-01 | Portela & Ca. S.A. | Nitrocatechol derivatives as comt inhibitors |
| EP1845097A1 (en) * | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| PT2124947T (pt) | 2007-01-31 | 2017-10-25 | BIAL-PORTELA & Cª S A | Regime posológico para inibidores da comt |
| AR070907A1 (es) | 2008-03-17 | 2010-05-12 | Bial Portela & Ca Sa | Formas cristalinas de derivado de nitrocatecol |
| RU2011144145A (ru) | 2009-04-01 | 2013-05-10 | Биал-Портела Энд Ка, С.А. | Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения |
| EP3626823A1 (en) | 2009-09-11 | 2020-03-25 | Ionis Pharmaceuticals, Inc. | Modulation of huntingtin expression |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| PT3604299T (pt) | 2011-12-13 | 2023-10-31 | Bial Portela & Ca Sa | Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase |
| RU2017120184A (ru) | 2014-11-28 | 2018-12-28 | БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. | Лекарства для замедления течения болезни паркинсона |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US576132A (en) * | 1897-02-02 | Current water-wheel | ||
| DE2364685C3 (de) | 1973-12-27 | 1978-06-15 | Beiersdorf Ag, 2000 Hamburg | Phenoxyäthylamine |
| US4438119A (en) * | 1982-12-23 | 1984-03-20 | Mead Johnson & Company | Method for alleviation of extrapyramidal motor disorders |
| CA1337429C (en) | 1983-12-05 | 1995-10-24 | Guy Rosalia Eugene Van Lommen | Derivatives of 2,2'-iminobisethanol |
| SE460947B (sv) * | 1986-08-26 | 1989-12-11 | Lejus Medical Ab | En multiple-unit-dos komposition av l-dopa |
| DE3901814A1 (de) * | 1988-07-28 | 1990-02-01 | Bayer Ag | Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga |
| EP0465254B1 (en) | 1990-07-06 | 1996-11-13 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused thiophene compounds and uses thereof |
| DE4135474A1 (de) | 1991-10-28 | 1993-04-29 | Bayer Ag | 2-aminomethyl-chromane |
| US5314888A (en) * | 1992-02-21 | 1994-05-24 | Trustees Of Tufts College | Veterinary method for treating inappropriate elimination of urine in household pets |
| SI9300097B (en) | 1992-02-27 | 2001-12-31 | Janssen Pharmaceutica Nv | (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines |
| WO1993017670A1 (en) | 1992-03-11 | 1993-09-16 | Interneuron Pharmaceuticals, Inc. | Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acids (lnaa) |
| DE4226527A1 (de) | 1992-08-11 | 1994-02-17 | Merck Patent Gmbh | 1,4-Benzodioxanderivate |
| GB9302622D0 (en) | 1993-02-10 | 1993-03-24 | Wellcome Found | Heteroaromatic compounds |
| US5744483A (en) * | 1994-01-31 | 1998-04-28 | Pfizer Inc. | Neuroprotective compounds |
| ZA954688B (en) | 1994-06-08 | 1996-01-29 | Lundbeck & Co As H | Serotonin 5-HT1A and dopamin D2 receptor ligands |
| EP0707007B1 (en) * | 1994-10-14 | 2001-12-12 | MERCK PATENT GmbH | (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane as CNS active agent |
| US5502080A (en) * | 1994-11-01 | 1996-03-26 | Hitzig; Pietr | Combined use of dopamine and serotonin agonists in the treatment of allergic disorders |
| US5554383A (en) * | 1995-04-06 | 1996-09-10 | Trustees Of Tufts College | Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression |
| US5541199A (en) * | 1995-06-02 | 1996-07-30 | American Home Products Corporation | Chroman-2-ylmethylamino derivatives |
| GB9514380D0 (en) | 1995-07-13 | 1995-09-13 | Knoll Ag | Therapeutic agents |
| JP4108747B2 (ja) * | 1995-07-13 | 2008-06-25 | アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 治療薬としてのピペラジン誘導体 |
| US5670667A (en) * | 1995-07-25 | 1997-09-23 | American Home Products Corporation | Chroman-2-ylmethylamino derivatives |
| US5756521A (en) * | 1996-04-03 | 1998-05-26 | American Home Products Corporation | Chroman-2-ylmethylamino derivatives |
| DE19648384A1 (de) | 1996-11-22 | 1998-05-28 | Merck Patent Gmbh | Fluorene, Dibenzofurane und Dibenzothiophene |
| EP0900792B1 (en) | 1997-09-02 | 2003-10-29 | Duphar International Research B.V | Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists |
| ATE253058T1 (de) * | 1997-09-02 | 2003-11-15 | Duphar Int Res | Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten |
| DE19751949A1 (de) * | 1997-11-24 | 1999-05-27 | Bayer Ag | Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration |
| EP1061924A1 (en) | 1998-03-09 | 2000-12-27 | Trustees Of Tufts College | Treatment of compulsive behaviours in man and animals |
| CA2330452A1 (en) | 1998-04-29 | 1999-11-04 | American Home Products Corporation | Antipsychotic indolyl derivatives |
| UA71590C2 (en) | 1998-11-13 | 2004-12-15 | Duphar Int Res | Piperazine and piperidine derivatives |
| UA73981C2 (en) * | 2000-03-10 | 2005-10-17 | Merck Patent Gmbh | (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit |
-
2002
- 2002-07-10 WO PCT/EP2002/007660 patent/WO2003009835A2/en active IP Right Grant
- 2002-07-10 DE DE60217870T patent/DE60217870T2/de not_active Expired - Lifetime
- 2002-07-10 MX MXPA04000775A patent/MXPA04000775A/es active IP Right Grant
- 2002-07-10 DK DK02790172T patent/DK1408964T3/da active
- 2002-07-10 CA CA2455621A patent/CA2455621C/en not_active Expired - Fee Related
- 2002-07-10 JP JP2003515228A patent/JP2004538289A/ja active Pending
- 2002-07-10 KR KR10-2003-7016837A patent/KR20040029325A/ko not_active Ceased
- 2002-07-10 BR BR0211358-9A patent/BR0211358A/pt not_active Application Discontinuation
- 2002-07-10 SI SI200230518T patent/SI1408964T1/sl unknown
- 2002-07-10 RU RU2004105844/15A patent/RU2297833C2/ru not_active IP Right Cessation
- 2002-07-10 EP EP02790172A patent/EP1408964B1/en not_active Expired - Lifetime
- 2002-07-10 AT AT02790172T patent/ATE352302T1/de active
- 2002-07-10 PL PL367291A patent/PL208258B1/pl not_active IP Right Cessation
- 2002-07-10 PT PT02790172T patent/PT1408964E/pt unknown
- 2002-07-10 US US10/484,697 patent/US7872030B2/en not_active Expired - Fee Related
- 2002-07-10 CN CNB028146794A patent/CN1292749C/zh not_active Expired - Fee Related
- 2002-07-10 HU HU0402092A patent/HUP0402092A3/hu unknown
- 2002-07-10 ES ES02790172T patent/ES2280602T3/es not_active Expired - Lifetime
- 2002-07-10 AU AU2002355170A patent/AU2002355170B2/en not_active Ceased
- 2002-07-22 MY MYPI20022758A patent/MY134059A/en unknown
- 2002-07-24 PE PE2002000652A patent/PE20030277A1/es not_active Application Discontinuation
- 2002-07-26 AR ARP020102823A patent/AR037496A1/es unknown
-
2007
- 2007-04-19 CY CY20071100526T patent/CY1107616T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20030277A1 (es) | 2003-03-25 |
| DE60217870D1 (de) | 2007-03-15 |
| HK1068793A1 (en) | 2005-07-29 |
| MY134059A (en) | 2007-11-30 |
| DK1408964T3 (da) | 2007-05-21 |
| SI1408964T1 (sl) | 2007-06-30 |
| CY1107616T1 (el) | 2013-03-13 |
| HUP0402092A2 (hu) | 2005-02-28 |
| KR20040029325A (ko) | 2004-04-06 |
| EP1408964B1 (en) | 2007-01-24 |
| PL367291A1 (en) | 2005-02-21 |
| ATE352302T1 (de) | 2007-02-15 |
| HUP0402092A3 (en) | 2010-06-28 |
| CN1535150A (zh) | 2004-10-06 |
| EP1408964A2 (en) | 2004-04-21 |
| AU2002355170B2 (en) | 2007-06-07 |
| AR037496A1 (es) | 2004-11-17 |
| WO2003009835A3 (en) | 2003-08-07 |
| WO2003009835A2 (en) | 2003-02-06 |
| RU2297833C2 (ru) | 2007-04-27 |
| CN1292749C (zh) | 2007-01-03 |
| PL208258B1 (pl) | 2011-04-29 |
| JP2004538289A (ja) | 2004-12-24 |
| ES2280602T3 (es) | 2007-09-16 |
| PT1408964E (pt) | 2007-05-31 |
| DE60217870T2 (de) | 2007-11-15 |
| CA2455621A1 (en) | 2003-02-06 |
| CA2455621C (en) | 2010-11-16 |
| US20040171645A1 (en) | 2004-09-02 |
| US7872030B2 (en) | 2011-01-18 |
| RU2004105844A (ru) | 2005-05-10 |
| MXPA04000775A (es) | 2004-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0213242A (pt) | Composto ou um seu sal ou solvato, composto e seus sais de adição de ácido fisiologicamente aceitáveis, composição farmacêutica, método de tratamento de um ou mais distúrbios, uso de um composto, e, processo de preparação de um composto | |
| BR0210122A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo | |
| BRPI0413555A (pt) | composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, método para o tratamento de uma doença, para a fabricação de um composto e para a preparação de composto | |
| BR0116370A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente. | |
| EP1040830A4 (en) | REMEDY FOR NEURODEGENERATIVE DISEASES | |
| BR0209468A (pt) | Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar | |
| BR0307050A (pt) | Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, sal farmaceuticamente aceitável, e, uso de um composto ou sal | |
| BR0308901A (pt) | ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose | |
| BR0212787A (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| BR0113590A (pt) | 7-oxo-piridopirimidinas | |
| CY1107616T1 (el) | Καινοτομος χρηση της 2-[5-(4-φθοροφαινυλο)-3-πυριδυλομεθυλαμινομεθυλο]-χρωμανης και των φυσιολογικα αποδεκτων αλατων της | |
| TR199701497T1 (xx) | Beyin �demini �nleyen terkip. | |
| ES2177024T3 (es) | Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer. | |
| BR0109119A (pt) | Uso de (r)-(-)-2-[5-(4-fluorofenil)-3-piridilmetil-aminometil]-cr omano e seus sais fisiologicamente aceitáveis | |
| BR0318659A (pt) | derivados de prolina usados como ingredientes farmacêuticos ativos no tratamento de tumores | |
| TR200103561T2 (tr) | Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları | |
| ES2173977T3 (es) | Uso de r-(z)-alfa-(metoxiimino)-alfa-(1-azabiciclo(2.2.2)oct-3-il)acetonitrilo para reducir la formacion de la proteina amilacea beta a4 en la enfermedad de alzheimer. | |
| BR0209985A (pt) | Composto e método para o tratamento de um paciente | |
| DK0420798T3 (da) | Antimikrobielle præparater | |
| BR9916244A (pt) | Utilização do riluzol ou de um de seus sais farmaceuticamente aceitáveis | |
| BR0317425A (pt) | Sal de rabeprazol, composição farmacêutica contendo o mesmo e processo para sua preparação | |
| BR0212199A (pt) | Uso de aminometil cromanos substituìdos no tratamento de distúrbios do movimento | |
| BR0316823A (pt) | Uso de levocetirizina ou um sal desta farmaceuticamente aceitável | |
| ES2109937T3 (es) | Uso de hexetidina o sus derivados o sales para la preparacion de una composicion farmaceutica para uso oftalmico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |